AG
LRMR icon

Algert Global’s Larimar Therapeutics LRMR Stock Holding History

Algert Global’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,030
Closed -$83.9K – 1253
2025
Q2 		$83.9K Buy
29,030
+5,750
+25% +$13.3K ﹤0.01% 1145
2025
Q1 		$50.1K Buy
23,280
+11,090
+91% +$35.1K ﹤0.01% 1153
2024
Q4 		$47.2K Buy
+12,190
New +$80.5K ﹤0.01% 1146
2019
Q1 		– Sell
-5,425
Closed -$322K – 356
2018
Q4 		$322K Sell
5,425
-738
-12% -$72.9K 0.09% 271
2018
Q3 		$865K Buy
6,163
+4,574
+288% +$555K 0.19% 190
2018
Q2 		$195K Sell
1,589
-587
-27% -$49.9K 0.04% 314
2018
Q1 		$195K Buy
+2,176
New +$184K 0.04% 310
2017
Q3 		– Sell
-2,929
Closed -$123K – 325
2017
Q2 		$123K Buy
+2,929
New +$150K 0.03% 281

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Algert Global's LRMR Position: Q3 2025 in Review

Algert Global sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 29,030 shares — an estimated $83.9K sold.

Algert Global first reported a position in LRMR in Q2 2017 and held it in 8 quarters. The position peaked at $865K in Q3 2018. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • Algert Global reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 29,030 Larimar Therapeutics shares in Q3 2025, an estimated $83.9K.
  • Algert Global first reported a position in Larimar Therapeutics in Q2 2017 and held it in 8 quarters.
  • Algert Global's Larimar Therapeutics position peaked at $865K in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.